Skip to main content

Abbott Laboratories COVID-19 Testing revenue

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B

COVID-19 Testing revenue at Abbott Laboratories came to $69.0M for the quarter to 30 Sep 2025, down 74.0% from a year earlier.

As Abbott Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2025.

By quarter

$730.0MMar 2023$263.0MJun 2023$305.0MSep 2023$300.0MDec 2023$204.0MMar 2024$102.0MJun 2024$265.0MSep 2024$176.0MDec 2024$55.0MJun 2025$69.0MSep 2025
Abbott Laboratories COVID-19 Testing revenue, every reported period
Period endingCOVID-19 Testing revenueChange on a yearFiled
30 Sep 2025$69.0Mdown 74.0%29 Oct 2025
30 Jun 2025$55.0Mdown 46.1%30 Jul 2025
31 Dec 2024$176.0Mdown 41.3%21 Feb 2025
30 Sep 2024$265.0Mdown 13.1%31 Oct 2024
30 Jun 2024$102.0Mdown 61.2%31 Jul 2024
31 Mar 2024$204.0Mdown 72.1%2 May 2024
31 Dec 2023$300.0M—16 Feb 2024
30 Sep 2023$305.0M—1 Nov 2023
30 Jun 2023$263.0M—3 Aug 2023
31 Mar 2023$730.0M—4 May 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Abbott Laboratories: Diabetes Care revenue · Core Laboratory revenue · Adult Nutritionals revenue · Key Emerging Markets revenue · Pediatric Nutritionals revenue · Cancer Diagnostics revenue · Rapid and Molecular revenue · Electrophysiology revenue · Vascular revenue · Rhythm Management revenue · Rapid Diagnostics revenue · Structural Heart revenue · Heart Failure revenue · Neuromodulation revenue · Point of Care revenue · Molecular revenue · Medical Devices revenue · Diagnostic Products revenue · Nutritional Products revenue · Established Pharmaceuticals revenue · financial statements

Every KPI and segment of ABT, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.